Navigation Links
Catching up with the Genomic Era in Oncology: Key Considerations for Incorporating Genomics into Oncology Drug Development, a New and Upcoming Webinar Hosted by Xtalks
Date:12/5/2013

Toronto, Canada (PRWEB) December 05, 2013

The integration of genomics into the process can be considered a third revolution in drug development in cancer. The first iteration was characterized by the development of classic cytotoxics such as aklylating agents. A second wave of change came with development of agents targeting specific molecular markers in the cancer cell such as Herceptin® for the over-expression of HER2. Today, the emerging understanding of the complex interplay of genomic alterations has led to a need to more fully understand the landscape of oncogenic drivers and drug targets present in an individual’s tumor. This complexity, and the genomic technologies developed to address it, present challenges to traditional drug development experts as well as clinicians. Quintiles’ experience has taught us that there is a need for drug developers to improve and expand their working understanding of genomics concepts and technologies in order maximize its value in drug development.

This webinar is intended to help oncology drug developers better understand key genomics concepts, technologies, and considerations for utilizing these approaches in their oncology programs, specifically:

  • Application of genomic DNA sequence profiling to help patient selection and speed timelines in oncology clinical trials
  • Technologies available for less invasive follow on testing, disease recurrence assessment, and patient management
  • The role of understanding RNA sequencing and expression microarrays in deciphering target mechanisms of action and pathway deregulation at the gene expression level
  • Platforms available for validating results and scaling up including 3rd generation sequencing platforms, high throughput genotyping platforms, and digital PCR

The audience can expect to gain the following insights:

  • The impact of genomics on the oncology clinical development process
  • Tangible opportunites and benefits of leveraging genomics in oncology clinical development
  • Key considerations for incorporating genomics into your oncology clinical programs
  • An understanding of the role of biomarkers in oncology clinical development and how cutting edge genomic technologies are being used to assess biomarkers
  • Technical considerations for selecting genomics platforms and addressing biological questions
  • An appreciation for the scope of bioinformatics needed to support genomics and key challenges of interpreting and managing genomic data

For more information on this webinar or to register, visit:
http://xtalks.com/Incorporating-Genomics-Oncology-Drug-Development.ashx
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com/ContactUs.ashx.

Contact:
Michelle Tran (416) 977-6555 ext 224
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/12/prweb11390246.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Forget about leprechauns, engineers are catching rainbows
2. Catching the cap-snatcher
3. Tute Genomics appoints Dr. Mingfu Zhu as Director of Bioinformatics
4. BioNano Genomics Announces the Adoption of Irys System by the Garvan Institute of Medical Research
5. Genomic Health and Almac Group Enter Exclusive In-Licensing Agreement to Develop and Commercialize Anthracycline Chemotherapy Benefit Test for High Risk Breast Cancer
6. Biogas Consortium Using Genedata Selector for Metagenomics-based Process Optimization
7. Healthcare VC Dr. Dinesh Patel to serve on Tute Genomics Board of Directors
8. Tute Genomics Launches at 2013 ASHG Conference
9. KEW Group Launches CancerPlex(SM) Assay to Bring State-of-the-Art Genomic Testing to Community Oncologists
10. BioNano Genomics Announces The Purchase Of The Irys System By The Chinese Academy Of Sciences And Tel Aviv University
11. Personal Genome Diagnostics and MolecularMD Collaborate to Provide Advanced Genomic Testing Services to Cancer Drug Developers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... , ... June 22, 2017 , ... ... leaders in designating infertility as a disease, bringing new hope for prospective parents ... their 2017 annual meeting to back the World Health Organization’s designation in hopes ...
(Date:6/22/2017)... ... June 22, 2017 , ... Tunnell ... the biopharma and life sciences industries, continue to be in demand for their ... Wolf will be speaking on “The State of Information Governance in the Biopharmaceutical ...
(Date:6/22/2017)... ... June 22, 2017 , ... RURO, Inc., ... Limfinity® version 6.5, a content-packed update to the Limfinity® framework. , LimitLIS® and ... and more diverse base of customers among labs and other businesses. Limfinity® 6.5 ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... CTNext board of directors has formed a Higher Education Entrepreneurship Advisory Committee to ... of institution presidents and other high-ranking representatives from 35 higher education institutions across ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):